Cor Vasa 2025, 67(4):541-547 | DOI: 10.33678/cor.2025.073

(Critical comments on the document "2024 ESC Guidelines for the management of elevated blood pressure and hypertension")

Renata Cífková^{a, b}, Aleš Linhart^b, Miloš Táborský^c

^a Centrum kardiovaskulární prevence, 1. lékařská fakulta Univerzity Karlovy a Fakultní Thomayerova nemocnice, Praha, Česká republika

^b II. interní klinika kardiologie a angiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha, Česká republika

^c Kardiologická klinika, Fakulta zdravotnických studií Univerzity J. E. Purkyně v Ústí nad Labem a Krajská zdravotní, a. s. - Masarykova nemocnice v Ústí nad Labem, o.z., Ústí nad Labem, Česká republika

The article is a critical appraisal of the Guidelines for the management of elevated blood pressure and hypertension, published by the European Society of Cardiology (ESC) in 2024, which were translated into Czech and published in this year's January supplement of the journal Cor et Vasa. The text draws attention to controversial aspects of the ESC guidelines, especially in the context of the guidelines of the European Society of Hypertension, published in 2023. The existence of two different European guidelines for the treatment of hypertension and "elevated blood pressure" is misleading for both doctors and patients.

Keywords: Antihypertensive medication, Betablockers, Goal blood pressure, Primary aldosteronism

Received: June 22, 2025; Accepted: June 27, 2025; Prepublished online: June 2, 2012; Published: October 6, 2025  Show citation